Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Unknown 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Gynecologic 2Dermatologic 2Breast 2Thoracic 1Genitourinary 1

Conditions

Melanoma 20Glioblastoma 12Neoplasms 10Breast Neoplasms 10Pancreatic Neoplasms 9Glioma 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Triple Negative Breast Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Colonic Neoplasms 5Urinary Bladder Neoplasms 4Sarcoma 4Fallopian Tube Neoplasms 4Carcinoma 4Astrocytoma 4Oligodendroglioma 3Neoplasms, Plasma Cell 3Lung Neoplasms 3Colorectal Neoplasms 3Central Nervous System Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Brain Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Skin Neoplasms 2Osteosarcoma 2Neoplasm Metastasis 2

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × poly ICLC × Clear all
NCT04116320 2025-07-14

AM-003

University of Virginia

Phase 1 Terminated
5 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma

NCT05281926 2022-03-16

A Phase I, Open-label Study to Assess the Safety and Efficacy of Poly-ICLC Plus Nivolumab in Unresectable Hepatocellular Carcinoma Patients

National Taiwan University Hospital

Phase 1 Unknown
10 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT00553683 2014-01-14

Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer

Rutgers, The State University of New Jersey

Phase 1/2 Unknown
50 enrolled
BreastDermatologicGastrointestinalGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Colonic Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡